Discovery of new pharmaceuticals for the treatment of cancer within the field of epigenetics.

Invested in 2010

Acquired by Gilead in 2015

Based in Foster City, California, USA 

Lundbeckfonden Emerge


Andreas Jurgeit
New Partner joins Lundbeckfonden Emerge
17. December 2018
IO Biotech announces first patient dosed in global phase I/II clinical trial for the first-line treatment of patients with metastatic non-small cell lung cancer
2. October 2018
Dermtreat Announces First Patient Dosed in Phase 2b Clinical Trial of Rivelin Clobetasol for Oral Lichen Planus
28. July 2018